Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes.

Literature DB >> 19561849

Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes.

Saloni Kapur¹, Mary Ellen Bonk.

Abstract

Entities: Gene

Year: 2009 PMID： 19561849 PMCID： PMC2697082

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

10 in total

1. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

Authors: Philip N Hawkins; Helen J Lachmann; Michael F McDermott
Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245

Review 2. Molecular and genetic characteristics of hereditary autoinflammatory diseases.

Authors: Mehmet Tunca; Huri Ozdogan
Journal: Curr Drug Targets Inflamm Allergy Date: 2005-02

Review 3. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes.

Authors: Anna Simon; Jos W M van der Meer
Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-08-24 Impact factor: 3.619

4. Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.

Authors: Samy K Metyas; Hal M Hoffman
Journal: J Rheumatol Date: 2006-09-15 Impact factor: 4.666

5. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome.

Authors: Susan M O'Connell; Grainne M O'Regan; Turlough Bolger; Hal M Hoffman; Andrew Cant; Alan D Irvine; Rosemarie M Watson
Journal: Pediatr Dermatol Date: 2007 Jan-Feb Impact factor: 1.588

6. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors: Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal: Arthritis Rheum Date: 2008-08

Review 7. Autoinflammatory diseases: an update of clinical and genetic aspects.

Authors: Q Yao; D E Furst
Journal: Rheumatology (Oxford) Date: 2008-04-03 Impact factor: 7.580

Review 8. Auto inflammatory syndromes: Diagnosis and treatment.

Authors: Katia Stankovic; Gilles Grateau
Journal: Joint Bone Spine Date: 2007-09-20 Impact factor: 4.929

Review 9. Autoinflammatory diseases: clinical and genetic advances.

Authors: Sharifeh Farasat; Ivona Aksentijevich; Jorge R Toro
Journal: Arch Dermatol Date: 2008-03

10. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.

Authors: Hal M Hoffman; Sanna Rosengren; David L Boyle; Jae Y Cho; Jyothi Nayar; James L Mueller; Justin P Anderson; Alan A Wanderer; Gary S Firestein
Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321

10 in total

17 in total

Review 1. Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors: Naomi Schlesinger
Journal: Drugs Date: 2011-07-30 Impact factor: 9.546

Review 2. Anti-interleukin-1 therapy in the management of gout.

Authors: Naomi Schlesinger
Journal: Curr Rheumatol Rep Date: 2014-02 Impact factor: 4.592

3. 3-Difluoroalkyl Quaternary Oxindoles Inhibit Macrophage Pyroptosis by Blocking Inflammasome Recruitment of Caspase-1.

Authors: Qi Xiao; Jin-Sheng Yu; Yufang Wang; Danjun Ma; Jian Zhou; Xin Lou
Journal: ACS Med Chem Lett Date: 2020-06-12 Impact factor: 4.345

Review 4. Co-opting biology to deliver drugs.

Authors: Parisa Yousefpour; Ashutosh Chilkoti
Journal: Biotechnol Bioeng Date: 2014-07-21 Impact factor: 4.530

5. Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1β during acute allergic airway inflammation.

Authors: M Ritter; K Straubinger; S Schmidt; D H Busch; S Hagner; H Garn; C Prazeres da Costa; L E Layland
Journal: Clin Exp Immunol Date: 2014-11 Impact factor: 4.330

6. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.

Authors: Norman T Ilowite; Kristi Prather; Yuliya Lokhnygina; Laura E Schanberg; Melissa Elder; Diana Milojevic; James W Verbsky; Steven J Spalding; Yukiko Kimura; Lisa F Imundo; Marilynn G Punaro; David D Sherry; Stacey E Tarvin; Lawrence S Zemel; James D Birmingham; Beth S Gottlieb; Michael L Miller; Kathleen O'Neil; Natasha M Ruth; Carol A Wallace; Nora G Singer; Christy I Sandborg
Journal: Arthritis Rheumatol Date: 2014-09 Impact factor: 10.995